Rznomics
Business Services · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Innovalley C Dong unit 801 Pangyo-ro 253...Website
www.rznomics.comRevenue
$6 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Rznomics
Rznomics specializes in the development of innovative RNA-based biopharmaceuticals aimed at addressing various unmet medical needs, particularly in the fields of cancer, degenerative diseases, and genetic disorders. The company focuses on gene therapy development for conditions such as liver cancer, brain tumors, Alzheimer's disease, and retinitis pigmentosa. With a strong emphasis on RNA platform technology, Rznomics aims to pioneer new modalities in RNA therapy through catalytic RNA rewriting. Their expertise lies in modular engineering and high-performance RNA targeting specific to disease-related pathways.Explore more
Rznomics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rznomics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Rznomics has new funding data
Product Launch: Get notified when Rznomics launches new products
Congratulate Masked Content for being promoted to Masked Content at Rznomics
Check if Rznomics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Rznomics recently announced quarterly report
Click to see if Rznomics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Rznomics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Rznomics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Rznomics as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Rznomics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Rznomics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Rznomics.
Rznomics Tech Stack
A closer look at the technologies used by Rznomics
Rznomics News & Media
Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026
Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim data from 10 enrolled patients A manageable safety profile, with prolonged disease control and tumor recurrence inhibition observed in several patients SEONGNAM and SEOUL, South Korea, June 15, 2026 /PRNewswire/ -- Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the Phase 1/2a interim clinical results for 'RZ-001 (TaspitimageRznomics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Granted to 'RZ-001' for Hepatocellular Carcinoma
RMAT designation based on promising Phase 1b/2a clinical data, including safety profile and preliminary response rates, with trans-splicing ribozyme-based RNA editing platform SEOUL, South Korea, May 8, 2026 /PRNewswire/ -- Rznomics a biopharmaceutical company specializing in RNA-based...Rznomics Reports Interim Clinical Data for RZ-001 in Hepatocellular Carcinoma at AACR 2026 Demonstrating Encouraging Efficacy and Favorable Safety Profile
– RECIST-based ORR of 38.5% (confirmed) and 46.2% (unconfirmed) – mRECIST-based ORR of 61.5% with a complete response (CR) rate of 23% – No Grade 3 or higher adverse events related to RZ-001 observed – Highlights clinical potential of RNA trans-splicing ribozyme platform technology SEOUL,...Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therapeutics
Co-development of precision RNA therapeutics for inherited hearing loss treatment SEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rznomics
Sign Up For FreeTo access detailed company insights
Rznomics specializes in the development of innovative RNA-based biopharmaceuticals aimed at addressing various unmet medical needs, particularly in the fields of cancer, degenerative diseases, and genetic disorders. The company focuses on gene therapy development for conditions such as liver cancer, brain tumors, Alzheimer's disease, and retinitis... Read More
